Viral Gastroenteritis Market Report 2025

The viral gastroenteritis market size has grown steadily in recent years. It will grow from $6.75 billion in 2024 to $7.08 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to the prevalence of viral infections, global hygiene practices, advancements in diagnostics, global travel and tourism, and climate and environmental factors.

The viral gastroenteritis market size is expected to see strong growth in the next few years. It will grow to $8.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to global health preparedness, climate change impact, one health approach, epidemiological surveillance systems, education and public awareness. Major trends in the forecast period include vaccine development, advanced diagnostics, telemedicine in diagnosis, collaborative research initiatives, personalized medicine approaches, and digital health solutions.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the viral gastroenteritis market in the future. Gastrointestinal (GI) disorders are diseases that affect any part of the gastrointestinal tract. Viral gastroenteritis treatments and diagnostic solutions provide appropriate medication for those suffering from the illness. For example, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn's disease and ulcerative colitis, reported a prevalence of 825 per 100,000 in 2023. This means that over 320,000 people in Canada have inflammatory bowel disease (IBD), and with an expected annual increase of 2.44%, it is projected that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Therefore, the rising prevalence of gastrointestinal disorders is driving the growth of the viral gastroenteritis market.

The growing awareness of hygiene and sanitation is expected to drive the growth of the viral gastroenteritis market in the future. Hygiene includes personal practices such as handwashing, waste disposal, and personal cleanliness to maintain a clean environment. Sanitation refers to providing facilities for safe waste disposal, water treatment, and ensuring a hygienic setting in homes, communities, and public spaces. Both hygiene and sanitation are essential in preventing the transmission of viruses that cause gastroenteritis. These measures help disrupt the fecal-oral transmission route, reduce contamination, and enhance overall community health by minimizing the risk and impact of viral gastroenteritis outbreaks. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based United Nations agency, reported that 57% of the global population, or 4.6 billion people, utilized safely managed sanitation services in 2022. This included 33% (2.7 billion) accessing private facilities connected to treated sewers, 21% (1.7 billion) using toilets or latrines that safely disposed of waste on-site, and 88% of the total population (7.2 billion) relying on at least basic sanitation services. Therefore, the increasing awareness of hygiene and sanitation is fueling the growth of the viral gastroenteritis market.

A prominent trend gaining momentum in the viral gastroenteritis market is product innovation. Major companies operating in this market are directing their efforts toward developing new products to fortify their market positions. For example, in November 2022, GlaxoSmithKline plc obtained approval from the US Food and Drug Administration (FDA) for an oral-dosing applicator-only presentation of ROTARIX, an oral vaccine to prevent rotavirus gastroenteritis in infants. This new presentation eliminates the need for reconstitution at the point of use, offering added convenience for healthcare providers. The approval is based on international clinical trial data demonstrating safety, tolerability, and immunogenicity compared to the lyophilized formulation.

Leading companies in the viral gastroenteritis market are introducing innovative products such as PCR kits for gastrointestinal infectious diseases to gain a competitive edge. PCR kits, also known as Polymerase Chain Reaction kits, are molecular biology tools designed for the amplification and detection of specific DNA sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd. launched 10 Real Time PCR Kits designed for the accurate detection of gastrointestinal pathogens. Covering a range of bacterial, viral, and parasitic pathogens associated with gastrointestinal infections, this solution provides a streamlined approach from sample pre-processing to PCR amplification analysis.

In January 2024, HilleVax Inc., a Switzerland-based biotech company, partnered with Chengdu Kanghua Biological Products Co. Ltd. This collaboration aims to develop HIL-216, a next-generation norovirus vaccine targeting six common genotypes, with clinical trials scheduled to begin in 2024 following FDA approval. Kanghua Biological Products Co. Ltd. is a China-based company dedicated to the development and manufacturing of biological products and vaccines for both veterinary and human health.

Major companies operating in the viral gastroenteritis market include Pfizer Inc., Abbvie Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, C.H. Boehringer Sohn AG & Co. KG, Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics Plc, Dr. Reddy’s Laboratories Ltd., BioMarin Pharmaceutical Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, Ironwood Pharmaceuticals Inc, ANI Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Allergan plc, Haustus Biotech Private Limited, Gracia Lifesciences India Private Limited.

North America was the largest region in the viral gastroenteritis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral gastroenteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Viral gastroenteritis is an intestinal viral infection characterized by swelling, irritation, and inflammation of the inner lining of the gastrointestinal tract. Common signs and symptoms include watery diarrhea, nausea or vomiting, stomach cramps, and fever.

The main types of drugs used in the treatment of viral gastroenteritis include antibiotics, antacids, laxatives, antimotility agents, and others. Antacids are medications that neutralize stomach acid to alleviate heartburn and indigestion. Diagnosis typically involves a physical examination and a rapid stool test, indicated by symptoms such as watery diarrhea, abdominal cramps, and pain. The various types of viruses associated with viral gastroenteritis include norovirus, rotavirus, astrovirus, and enteric adenovirus. These drugs and diagnostic procedures are utilized by various end-users, including hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers, and others.

The viral gastroenteritis market research report is one of a series of new reports that provides viral gastroenteritis market statistics, including viral gastroenteritis industry global market size, regional shares, competitors with a viral gastroenteritis market share, detailed viral gastroenteritis market segments, market trends, and opportunities, and any further data you may need to thrive in the viral gastroenteritis industry. This viral gastroenteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral gastroenteritis market consists of revenues earned by entities by providing various diagnostics such as polymerase chain reaction testing and immunoassays. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral gastroenteritis market also includes sales of antiemetics, and chemotherapy drugs used for treating viral gastroenteritis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.